Transcatheter Closure of Patent Foramen Ovale: A Single Center Experience

  • Ivan Milev Special Hospital for Surgical Diseases "Filip Vtori", Cardiology, Skopje
  • Planinka Zafirovska Special Hospital for Surgical Diseases "Filip Vtori", Cardiology, Skopje
  • Zan Zimbakov Special Hospital for Surgical Diseases "Filip Vtori", Cardiology, Skopje
  • Shpend Idrizi
  • Vilma Ampova-Sokolov Special Hospital for Surgical Diseases "Filip Vtori", Cardiology, Skopje
  • Emilija Gorgieva Special Hospital for Surgical Diseases "Filip Vtori", Cardiology, Skopje
  • Liljana Ilievska Special Hospital for Surgical Diseases "Filip Vtori", Cardiology, Skopje
  • Goce Tosheski Special Hospital for Surgical Diseases "Filip Vtori", Cardiology, Skopje
  • Nikola Hristov Special Hospital for Surgical Diseases "Filip Vtori", Cardiology, Skopje
  • Ljubica Georgievska-Ismail University Clinic of Cardiology, Faculty of Medicine, Ss Cyril and Methodius University of Skopje, Skopje
  • Tanja Anguseva Special Hospital for Surgical Diseases "Filip Vtori", Cardiology, Skopje
  • Zan Mitrev Special Hospital for Surgical Diseases "Filip Vtori", Cardiology, Skopje
Keywords: patent foramen ovale, transcatheter closure, cerebrovascular insult, a migraine, interventional closure


BACKGROUND: Percutaneous transcatheter closure (PTC) of patent foramen ovale (PFO) is implicated in cryptogenic stroke, transitional ischemic attack (TIA) and treatment of a migraine.

AIM: Our goal was to present our experience in the interventional treatment of PFO, as well as to evaluate the short and mid-term results in patients with closed PFO.

MATERIAL AND METHODS: Transcatheter closure of PFO was performed in 52 patients (67.3% women, mean age 40.7 ± 11.7 years). Patients were interviewed for subjective grading of the intensity of headaches before and after the PFO closure.

RESULTS: During 2 years of follow-up, there was no incidence of new stroke, TIA and/or syncope. Follow-up TCD performed in 35 patients showed complete PFO closure in 20 patients (57.1%). Out of 35 patients, 22 (62.9%) reported having a migraine before the procedure with an intensity of headaches at 8.1 ± 1.9 on a scale from 1 to 10. During 2 years of follow-up, symptoms of a migraine disappeared in 4 (18.2%) and the remaining 18 patients reported the significant decrease in intensity 4.8 ± 2.04 (p = 0.0001). In addition, following PFO closure the incidence of the headaches decreased significantly (p = 0.0001).

CONCLUSIONS: Percutaneous transcatheter closure of PFO is a safe and effective procedure showing mid-term relief of neurological symptoms in patients as well as significant reduction of migraine symptoms.


Download data is not yet available.


Metrics Loading ...

Plum Analytics Artifact Widget Block


Hagen PT, Scholz DG, Edwards WD. Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin Proc. 1984;59(1):17-20.

Seiler C. Patent foramen ovale (PFO): is there life before death in the presence of PFO? Eur J Clin Invest. 2015;45(8):875-882. PMid:26017145

Serena J, Jiménez-Nieto M, Silva Y, Castellanos M. Patent foramen ovale in cerebral infarction. Curr Cardiol Rev. 2010;6(3):162-174. PMid:21804775 PMCid:PMC2994108

Kent DM, Thaler DE. Is patent foramen ovale a modifiable risk factor for stroke recurrence? Stroke. 2010;41(10 Suppl):S26-S30. PMid:20876498 PMCid:PMC2954503

Mirzaali M, Dooley M, Wynne D, Cooter N, Lee L, Haworth P, Saha R, Gainsborough N, Hildickâ€Smith D. Patent foramen ovale closure following cryptogenic stroke or transient ischaemic attack: Longâ€term followâ€up of 301 cases. Catheterization and Cardiovascular Interventions. 2015;86(6):1078-84. PMid:26105198

Rigatelli G, Dell'avvocata F, Cardaioli P, et al. Improving migraine by means of primary transcatheter patent foramen ovale closure: long-term follow-up. Am J Cardiovasc Dis. 2012;2(2):89-95. PMid:22720197 PMCid:PMC3371619

Smart D, Mitchell S, Wilmshurst P, Turner M, Banham N. Joint position statement on persistent foramen ovale (PFO) and diving. South Paciï¬c Underwater Medicine Society (SPUMS) and the United Kingdom Sports Diving Medical Committee (UKSDMC). Diving Hyperb Med. 2015;45(2):129-131. PMid:26165538

Honěk J, Šefc L, Honěk T, Šrámek M, Horváth M, Veselka J. Patent Foramen Ovale in Recreational and Professional Divers: An Important and Largely Unrecognized Problem. Can J Cardiol. 2015;31(8):1061-1066. PMid:26143138

Overell JR, Bone I, Lees KR. Interatrial septal abnormalities and stroke: a meta-analysis of case-control studies. Neurology. 2000;55(8):1172-1179. PMid:11071496

Kent DM, Dahabreh IJ, Ruthazer R, et al. Anticoagulant vs. antiplatelet therapy in patients with cryptogenic stroke and patent foramen ovale: an individual participant data meta-analysis. Eur Heart J. July 2015. PMid:26141397 PMCid:PMC4568404

Tobis J, Mojadidi, Khessali, Levinson R, Tobis J. Visual migraine aura with or without headache: association with right to left shunt and assessment following transcutaneous closure. Clin Ophthalmol. 2012:1099. PMid:22888208 PMCid:PMC3413347

Guidetti D, Rota E, Morelli N, Immovilli P. Migraine and stroke: "vascular" comorbidity. Front Neurol. 2014;5:193. PMid:25339937 PMCid:PMC4189436

Manuscript A. NIH Public Access. Changes. 2012;29(6):997-1003.

Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP. Atrial anatomy in non-cardioembolic stroke patients: effect of medical therapy. J Am Coll Cardiol. 2003;42(6):1066-1072.

Fox ER, Picard MH, Chow C-M, Levine RA, Schwamm L, Kerr AJ. Interatrial septal mobility predicts larger shunts across patent foramen ovales: An analysis with transmitral Doppler scanning. Am Heart J. 2003;145(4):730-736. PMid:12679772

Davis D, Gregson J, Willeit P, Stephan B, Al-Shahi Salman R, Brayne C. Patent Foramen Ovale, Ischemic Stroke and Migraine: Systematic Review and Stratified Meta-Analysis of Association Studies. Neuroepidemiology. 2013;40(1):56-67. PMid:23075508 PMCid:PMC3707011

Meschia JF, Bushnell C, Boden-Albala B, et al. Guidelines for the Primary Prevention of Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2014;45(12):3754-3832. PMid:25355838 PMCid:PMC5020564

Schürks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T. Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ. 2009;339:b3914. PMid:19861375 PMCid:PMC2768778

Alsheikh-Ali AA, Thaler DE, Kent DM. Patent foramen ovale in cryptogenic stroke: incidental or pathogenic? Stroke. 2009;40(7):2349-2355. PMid:19443800 PMCid:PMC2764355

Schwedt TJ, Demaerschalk BM, Dodick DW. Patent foramen ovale and migraine: a quantitative systematic review. Cephalalgia. 2008;28(5):531-540. PMid:18355348

Wahl A, Praz F, Tai T, et al. Improvement of migraine headaches after percutaneous closure of patent foramen ovale for secondary prevention of paradoxical embolism. Heart. 2010;96(12):967-973. PMid:20538672

Bridges ND, Hellenbrand W, Latson L, Filiano J, Newburger JW, Lock JE. Transcatheter closure of patent foramen ovale after presumed paradoxical embolism. Circulation. 1992;86(6):1902-1908. PMid:1451261

Meier B. Patent foramen ovale and closure technique with the amplatzer occluder. Scientifica. 2014;2014.

Furlan AJ, Reisman M, Massaro J, et al for the CLOSURE I Investigators. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med. 2012;366(11):991-999. PMid:22417252

Meier B, Kalesan B, Mattle HP, et al. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med. 2013;368(12):1083-1091. PMid:23514285

Carroll JD, Saver JL, Thaler DE, et al. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med. 2013;368(12):1092-1100. PMid:23514286

Hammerstingl C, Bauriedel B, Stüsser C, et al. Risk and fate of residual interatrial shunting after transcatheter closure of patent foramen ovale: a long term follow up study. Eur J Med Res. 2011;16(1):13-19. PMid:21345765 PMCid:PMC3351944

Saver JL, Thaler DE, Smalling RW, et al. Qualifying and Outcome Strokes in the RESPECT PFO Trial : Additional Evidence of Treatment Effect Disclosure Statement of Financial Interest.

Stortecky S, da Costa BR, Mattle HP, et al. Percutaneous closure of patent foramen ovale in patients with cryptogenic embolism: a network meta-analysis. Eur Heart J. 2015;36(2):120-128. PMid:25112661

Nietlispach F, Meier B. Percutaneous closure of patent foramen ovale: safe and effective but underutilized. Expert Rev Cardiovasc Ther. 2015;13(2):121-123. PMid:25556896

Tobis J, Shenoda M. Percutaneous treatment of patent foramen ovale and atrial septal defects. J Am Coll Cardiol. 2012;60(18):1722-1732. PMid:23040567

Elmariah S, Furlan AJ, Reisman M, et al. Predictors of recurrent events in patients with cryptogenic stroke and patent foramen ovale within the CLOSURE I (Evaluation of the STARFlex Septal Closure System in Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embol. JACC Cardiovasc Interv. 2014;7(8):913-920. PMid:25147037

57th Annual Scientific Meeting | American Headache Society. Accessed August 23, 2015.

Mattle HP, Evers S, Hildick-Smith D, et al. Percutaneous closure of patent foramen ovale in migraine with aura, a randomized controlled trial. Eur Heart J. 2016; 37:2029-36. PMid:26908949

Kent DM, Dahabreh IJ, Ruthazer R, et al. Device closure of patent foramen ovale after stroke: Pooled analysis of completed randomized trials. J Am Coll Cardiol. 2016; 67(8):907-17. PMid:26916479

Meier B, Frank B, Wahl A, Diener HC. Secondary stroke prevention: Patent foramen ovale, aortic plaque, and carotid stenosis. Eur Heart J. 2012;33(6):705-713. PMid:22422912 PMCid:PMC3303713

Mirzada N, Ladenvall P, Hansson PO, Eriksson P, Dellborg M. Multidisciplinary management of patent foramen ovale (PFO) and cryptogenic stroke/TIA. J Multidiscip Healthc. 2013;6:357-363. PMid:24082787 PMCid:PMC3785383

Van de Bruaene A, Stroobants D, Benit E. Percutaneous closure of inter-atrial communications (atrial septal defect and patent foramen ovale): single-centre experience and mid-term follow-up. Acta Cardiol. 2015;70(2):133-140. PMid:26148372

Spencer F a, Lopes LC, Kennedy S a, Guyatt G. Systematic review of percutaneous closure versus medical therapy in patients with cryptogenic stroke and patent foramen ovale. BMJ Open. 2014;4(3):e004282. PMid:24607561 PMCid:PMC3948581

Tanzi A, Onorato E, Casilli F, Anzola GP. Is the search for right-to-left shunt still worthwhile? Acta Neurol Scand. 2015. PMid:26139358

How to Cite
Milev I, Zafirovska P, Zimbakov Z, Idrizi S, Ampova-Sokolov V, Gorgieva E, Ilievska L, Tosheski G, Hristov N, Georgievska-Ismail L, Anguseva T, Mitrev Z. Transcatheter Closure of Patent Foramen Ovale: A Single Center Experience. Open Access Maced J Med Sci [Internet]. 2016Oct.5 [cited 2021Jan.18];4(4):613-8. Available from:
B - Clinical Sciences

Most read articles by the same author(s)